The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

F. Forzano; O. Antonova; A. Clarke; G. de Wert; S. Hentze; Y. Jamshidi; Y. Moreau; M. Perola; I. Prokopenko; A. Read; A. Reymond; V. Stefansdottir; C. van El; M. Genuardi; Executive Committee of the European Society of Human Genetics; Public and Professional Policy Committee of the European Society of Human Genetics

doi:10.1038/s41431-021-01000-x

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

F. Forzano^*, O. Antonova, A. Clarke, G. de Wert, S. Hentze, Y. Jamshidi, Y. Moreau, M. Perola, I. Prokopenko, A. Read, A. Reymond, V. Stefansdottir, C. van El, M. Genuardi, Executive Committee of the European Society of Human Genetics, Public and Professional Policy Committee of the European Society of Human Genetics

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Y Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

Original language	English
Pages (from-to)	493-495
Number of pages	3
Journal	European Journal of Human Genetics
Volume	30
Issue number	5
Early online date	17 Dec 2021
DOIs	https://doi.org/10.1038/s41431-021-01000-x
Publication status	Published - May 2022

Access to Document

10.1038/s41431-021-01000-xLicence: CC BY

2 Erratum / corrigendum / retractions

Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Forzano, F., Antonova, O., Clarke, A., de Wert, G., Hentze, S., Jamshidi, Y., Moreau, Y., Perola, M., Prokopenko, I., Read, A., Reymond, A., Stefansdottir, V., van El, C., Genuardi, M. & Executive Committee of the European Society of Human Genetics, May 2022, In: European Journal of Human Genetics. 30, 5, p. 628-628 1 p., 628.
Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Open Access
Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Forzano, F., Antonova, O., Clarke, A., de Wert, G., Hentze, S., Jamshidi, Y., Moreau, Y., Perola, M., Prokopenko, I., Read, A., Reymond, A., Stefansdottir, V., van El, C., Genuardi, M. & Executive Committee of the European Society of Human Genetics, Nov 2022, In: European Journal of Human Genetics. 30, 11, p. 1306-1306 1 p.
Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Open Access

Cite this

Forzano, F., Antonova, O., Clarke, A., de Wert, G., Hentze, S., Jamshidi, Y., Moreau, Y., Perola, M., Prokopenko, I., Read, A., Reymond, A., Stefansdottir, V., van El, C., Genuardi, M., Executive Committee of the European Society of Human Genetics, & Public and Professional Policy Committee of the European Society of Human Genetics (2022). The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice. European Journal of Human Genetics, 30(5), 493-495. https://doi.org/10.1038/s41431-021-01000-x

@article{7273d38d452440a28d925dab3ee5a865,

title = "The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice",

abstract = "Y Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.",

author = "F. Forzano and O. Antonova and A. Clarke and {de Wert}, G. and S. Hentze and Y. Jamshidi and Y. Moreau and M. Perola and I. Prokopenko and A. Read and A. Reymond and V. Stefansdottir and {van El}, C. and M. Genuardi and {Executive Committee of the European Society of Human Genetics} and {Public and Professional Policy Committee of the European Society of Human Genetics}",

note = "Funding Information: IP has received funding from the World Cancer Research Fund (WCRF UK) and World Cancer Research Fund International (2017/1641), the European Union{\textquoteright}s Horizon 2020 research and innovation programme (LONGITOOLS, H2020-SC1-2019-874739), the Ministry of Science and Higher Education of Russian Federation (075-15-2021-595), Agence Nationale de la Recherche (PreciDIAB, ANR-18-IBHU-0001), the European Union through the “Fonds europ{\'e}en de d{\'e}veloppement regional” (FEDER), the “Conseil R{\'e}gional des Hauts-de-France” (Hauts-de-France Regional Council), and the “M{\'e}tropole Europ{\'e}enne de Lille” (MEL, European Metropolis of Lille).",

year = "2022",

month = may,

doi = "10.1038/s41431-021-01000-x",

language = "English",

volume = "30",

pages = "493--495",

journal = "European Journal of Human Genetics",

issn = "1018-4813",

publisher = "Nature Publishing Group",

number = "5",

}

Forzano, F, Antonova, O, Clarke, A, de Wert, G, Hentze, S, Jamshidi, Y, Moreau, Y, Perola, M, Prokopenko, I, Read, A, Reymond, A, Stefansdottir, V, van El, C, Genuardi, M, Executive Committee of the European Society of Human Genetics & Public and Professional Policy Committee of the European Society of Human Genetics 2022, 'The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice', European Journal of Human Genetics, vol. 30, no. 5, pp. 493-495. https://doi.org/10.1038/s41431-021-01000-x

TY - JOUR

T1 - The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

AU - Forzano, F.

AU - Antonova, O.

AU - Clarke, A.

AU - de Wert, G.

AU - Hentze, S.

AU - Jamshidi, Y.

AU - Moreau, Y.

AU - Perola, M.

AU - Prokopenko, I.

AU - Read, A.

AU - Reymond, A.

AU - Stefansdottir, V.

AU - van El, C.

AU - Genuardi, M.

AU - Executive Committee of the European Society of Human Genetics

AU - Public and Professional Policy Committee of the European Society of Human Genetics

N1 - Funding Information: IP has received funding from the World Cancer Research Fund (WCRF UK) and World Cancer Research Fund International (2017/1641), the European Union’s Horizon 2020 research and innovation programme (LONGITOOLS, H2020-SC1-2019-874739), the Ministry of Science and Higher Education of Russian Federation (075-15-2021-595), Agence Nationale de la Recherche (PreciDIAB, ANR-18-IBHU-0001), the European Union through the “Fonds européen de développement regional” (FEDER), the “Conseil Régional des Hauts-de-France” (Hauts-de-France Regional Council), and the “Métropole Européenne de Lille” (MEL, European Metropolis of Lille).

PY - 2022/5

Y1 - 2022/5

N2 - Y Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

AB - Y Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

U2 - 10.1038/s41431-021-01000-x

DO - 10.1038/s41431-021-01000-x

M3 - Editorial

C2 - 34916614

SN - 1018-4813

VL - 30

SP - 493

EP - 495

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

IS - 5

ER -

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Abstract

Access to Document

Research output

Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Cite this